PR PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024
      2024. 03. 22

       PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024



      SEONGNAM, South Korea PharmaResearch, a leading pharmaceutical/medical device research company, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, scheduled from April 5th to 10th in San Diego, California. The company will unveil research findings regarding its groundbreaking anticancer agent, PRD-101, through a poster session.


      The presentations will cover diverse topics, including the efficacy demonstrated in various patient-derived xenograft (PDX) animal models and the results of in-depth characterization conducted by the National Cancer Institute’s Nanotechnology Characterization Laboratory (NCL).


      Presentation Details


      Poster Title: Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study
      Date and Time: Tuesday April 9, 1:30 AM - 5:00 PM PT


      Session Category: Chemistry
      Session Title:
      Drug Delivery
      Session Location:
      Section 20
      Poster Board Number: 3
      Abstract number:


      About PharmaResearch’s PRD-101


      PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimization technology (DOTTM) in nano-particle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive license associated with PRD-101, marking a milestone in the company's innovative endeavors.


      Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. The company is committed to advancing quickly into clinical trials based on promising safety and efficacy results obtained from preclinical studies.


      About PharmaResearch


      PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOTTM PDRN and DOTTM PN. These active tissue regenerative substances are powered by DOTTM, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa, Califrornia, US.


      PharmaResearch's participation in the AACR Annual Meeting underscores its dedication to pioneering advancements in cancer research and treatment, ultimately aiming to improve patient outcomes and quality of life.


      For more information about PharmaResearch and its innovative initiatives, visit and connect with us on LinkedIn.